A Preliminary Investigation of α-Lipoic Acid Treatment of Antipsychotic Drug-Induced Weight Gain in Patients With Schizophrenia
Authors:
- Eosu KimEKEosu Kim
- Dong-Wha ParkDPDong-Wha Park
- Song-Hee ChoiSCSong-Hee Choi
- Jae-Jin KimJae-Jin Kim
- Hyun-Sang ChoHCHyun-Sang Cho
- 1 April 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 28 (2) , 138-146
Abstract
Weight gain and other metabolic disturbances have now become discouraging, major side effects of atypical antipsychotic drugs (AAPDs). The novel strategies required to counteract these serious consequences, however, should avoid modulating the activities of the neurotransmitter receptors involved because those receptors are the therapeutic targets of AAPDs. Adenosine monophosphate-activated protein kinase is an enzyme that plays a pivotal role in energy homeostasis. We hypothesized that α-lipoic acid (ALA), which is known to modulate adenosine monophosphate-activated protein kinase activity in the hypothalamus and peripheral tissues, would ameliorate AAPD-induced weight gain. We describe the case series of a 12-week ALA trial in schizophrenia patients treated with AAPDs. Two of 7 enrolled subjects were dropped from the study because of noncompliance and demand for new medication to treat depressive symptoms, respectively. The mean (SD) weight loss was 3.16 (3.20) kg (P = 0.043, last observation carried forward; median, 3.03 kg; range, 0-8.85 kg). On average, body mass index showed a significant reduction (P = 0.028) over the 12 weeks. During the same period, a statistically significant reduction was also observed in total cholesterol levels (P = 0.042), and there was a weak trend toward the reduction in insulin resistance (homeostasis model assessment of insulin resistance) (P = 0.080). Three subjects reported increased energy subjectively. The total scores on the Brief Psychiatric Rating Scale and the Montgomery-Asberg Depression Rating Scale did not vary significantly during the study. These preliminary data suggest the possibility that ALA can ameliorate the adverse metabolic effects induced by AAPDs. To confirm the benefits of ALA, more extended study is warranted.Keywords
This publication has 55 references indexed in Scilit:
- Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivoAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food IntakeCell Metabolism, 2007
- Expanding role of AMPK in endocrinologyTrends in Endocrinology & Metabolism, 2006
- AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolismCell Metabolism, 2005
- Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinaseNature Medicine, 2004
- AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamusNature, 2004
- Update on Adipocyte HormonesDiabetes, 2004
- Options for pharmacological management of obesity in patients treated with atypical antipsychoticsInternational Clinical Psychopharmacology, 2002
- Estimating the consequences of anti-psychotic induced weight gain on health and mortality ratePsychiatry Research, 2001
- Alpha-lipoic acid as a biological antioxidantFree Radical Biology and Medicine, 1995